13 Quản lý suy tim mạn đa chuyên khoa (QLSTĐCK)
13.7 Theo dõi từ xa (TDTX)
Theo dõi từ xa (triệu chứng, cân nặng, nhịp tim …) cho phép bệnh nhân cung cấp thông tin về tình trạng sức khỏe để nhận được hỗ trợ và chăm sóc tối ưu (trực tiếp hoặc thơng qua nhân viên y tế), để tối ưu điều trị hoặc tìm kiếm những hỗ trợ chăm sóc khác, giúp duy trì chất lượng chăm sóc, tạo điều kiện để bệnh nhân có thể nhanh chóng tiếp cận dịch vụ y tế khi cần thiết, giảm chi phí đi lại và giảm thiểu tần suất khám bệnh (192).
TDTX rất đa dạng, có thể được cung cấp tại địa phương, theo vùng hoặc theo quốc gia, nên tập trung vào việc tối ưu hóa quản lý, chăm sóc hơn là phát hiện và xử trí các trường hợp khẩn cấp y tế, do vậy thường chỉ cần nhân viên làm việc trong giờ hành chính. Một số hệ thống cũng được thiết kế để hỗ trợ bất cứ lúc nào bệnh nhân yêu cầu, dự báo và xử lý các giai đoạn trở nặng của bệnh … nhưng chưa thành cơng do có q nhiều các cảnh báo giả (193). TDTX là một phương pháp hiệu quả để giáo dục bệnh nhân, hỗ trợ chăm sóc y tế và tạo động lực hướng tới chăm sóc sức khỏe.
Nhiều thiết bị trị liệu khơng dây được cấy ghép có thể cung cấp từ xa các thông tin như các rối loạn nhịp, hoặc về các tình trạng sinh lý khác của bệnh nhân (tần số tim, hoạt động, tiếng tim, trở kháng sinh học) trên chính thiết bị. Có bằng chứng chắc chắn rằng việc theo dõi như vậy có thể phát hiện sự cố của thiết bị sớm hơn so với thơng thường và có thể hữu ích để phát hiện các rối loạn nhịp như rung nhĩ. Tuy nhiên, có ít bằng chứng cho thấy thiết bị theo dõi giảm tỷ lệ nhập viện do suy tim hoặc tử vong(194).
Chúng ta sẽ chờ thêm các bằng chứng về hiệu quả quản lý bệnh qua các dữ liệu từ các thiết bị cấy(195).
139
TÀI LIỆU THAM KHẢO
1. Bozkurt B, Coats AJS, Tsutsui H et al. Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure 2021; 27:387-413
2. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment
of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3. Maddox TM, Januzzi JL, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. ACC 2021; 77:772 – 810
4. Brouwers FP, de Boer RA, van der Harst et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow- up of PREVEND. Eur Heart J (2013) 34, 1424–1431
5. Reyes EB, Ha JW, Firdaus I et al. Heart failure across Asia: Same healthcare burden but differences in organization of care. Int J Cardiol. 2016 Nov 15;223:163-167
6. Chioncel O, Lainscak M, Seferovic PM et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017 Dec;19(12):1574-1585 7. Gerber Y, Weston SA, Redfield MM, et al. A Contemporary Appraisal of the Heart Failure
Epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996– 1004.
8. Tsao CW, Lyass A, Enserro D et al. emporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018 Aug;6(8):678-685.
9. Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, Rouleau J, Shi V, Lefkowitz M, McMurray JJV. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail 2016;4:816-822.
10. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
11. Packer M, Anker SD, Butler J et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424.
12. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B, SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117-128.
140
13. Bohm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013;102:11-22.
14. Abdul-Rahim AH, Shen L, Rush CJ et al. Effect of digoxin in patients with heart failure and mid- range (borderline) left ventricular ejection fraction. Eur J Heart Fail 2018;20:1139-1145
15. Armstrong PW, Pieske B, Anstrom KJ et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883-1893.
16. Teerlink JR, Diaz R, Felker GM et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med 2021;384:105-116.
17. Kober L, Thune JJ, Nielsen JC et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221-1230.
18. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
19. Cleland JG, Daubert JC, Erdmann E et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-1932.
20. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-2150. 21. Tang AS, Wells GA, Talajic M et al. Cardiac-resynchronization therapy for mild-to-moderate
heart failure. N Engl J Med 2010;363:2385-2395.
22. Goldenberg I, Kutyifa V, Klein HU et al. Survival with cardiacresynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694-1701.
23. Linde C, Gold MR, Abraham WT et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013;34:2592-2599
24. Curtis AB, Worley SJ, Adamson PB et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585-1593.
25. Steffel J, Robertson M, Singh JP et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J 2015;36:1983-1989.
26. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345
27. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781.
141
28. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
29. Solomon SD, Claggett B, Lewis EF et al. TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 2016;37:455-462.
30. Solomon SD, McMurray JJV, Anand IS et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620.
31. Solomon SD, Vaduganathan M, Claggett BL et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352-361.
32. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. the EMPEROR-Preserved Trial. n engl j med. DOI: 10.1056/NEJMoa2107038. 33. Cleland JGF, Bunting KV, Flather MD et al. Beta-blockers for heart failure with reduced, mid-
range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35.
34. Shah SJ, Feldman T, Ricciardi MJ et al. One year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial. JAMA Cardiol 2018;3:968-977.
35. Borlaug. BA: Treatment and prognosis of heart failure with mid-range ejection fraction. Uptodate 2021.
36. Adelstein. E, Saba. SM. Cardiac resynchronization therapy in heart failure: Indications. Uptodate 2021.
37. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-573.
38. Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverterdefibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol 2014;63:2388-2394.
39. Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861-870.
142
40. Pieske B, Tschope C, de Boer RA et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297-3317
41. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, Naftel DC, Ulisney K, Desvigne-Nickens P, Kirklin JK. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009;28:535-541.
42. Barandiaran Aizpurua A, Sanders-van Wijk S et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail 2020;22:413-421. 43. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart
failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61-73.
44. Tsutsui H, Isobe M, ItoH et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circ J. 2019 Sep 25;83(10):2084-2184.
45. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158.
46. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-254.
47. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326-2331.
48. Cannon CP, Pratley R, Dagogo-Jack S et al. VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383:1425-1435
49. Neal B, Perkovic V, Mahaffey KW et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657. 50. Wiviott SD, Raz I, Bonaca MP, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and
cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357.
51. Zinman B, Wanner C, Lachin JM et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. 52. Dorans KS, Mostofsky E, Levitan EB, et al. Alcohol and incident heart failure among middle-
aged and elderly men: cohort of Swedish men. Circ Heart Fail 2015;8:422-427
53. Goncalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur Heart J 2015;36:939-945.
143
54. Padwal R, McAlister FA, McMurray JJ, et al. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes (Lond) 2014;38:1110- 1114.
55. Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015;132:1786-1794.
56. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
57. Rogers JG, Butler J, Lansman SL et al. Chronic mechanical circulatory support for inotrope- dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007;50:741-747.
58. Starling RC, Estep JD, Horstmanshof DA et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. JACC Heart Fail 2017;5:518-527.
59. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, Aaronson KD, Frazier OH, Milano CA. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 2017;376:451-460.
60. Mehra MR, Uriel N, Naka Y et al. A fully magnetically levitated left ventricular assist device – final report. N Engl J Med 2019;380:1618-1627.
61. Slaughter MS, Pagani FD, McGee EC et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013;32:675-683.
62. Karason K, Lund LH, Dalen M et al. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. Eur J Heart Fail 2020;22:739-750
63. Thiele H, Zeymer U, Thelemann N et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP- SHOCK II Trial. Circulation 2019;139:395-403.
64. Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373.
65. Kotecha D, Bunting KV, Gill SK et al. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020;324:2497-2508.
66. Abdelrahman M, Subzposh FA, Beer D et al. Clinical outcomes of His bundle pacing compared to right ventricular pacing. J Am Coll Cardiol 2018;71:2319-233
144
67. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;37:1677- 1682.
68. Kirchhof P, Camm AJ, Goette A et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305-1316.
69. Marrouche NF, Brachmann J, Andresen D et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-427.
70. Packer DL, Mark DB, Robb RA et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261-1274.
71. Kuck KH, Merkely B, Zahn R et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731..
72. Di Biase L, Mohanty P, Mohanty S et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016;133:1637-1644.
73. Zannad F, Anker SD, Byra WM et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379: 1332-1342.
74. Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-1616
75. Cleland JG, Calvert M, Freemantle N et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail 2011;13:227-233
76. Perera D, Clayton T, Petrie MC et al. Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy. JACC Heart Fail 2018;6:517-526.
77. Obadia JF, Messika-Zeitoun D, Leurent G et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:22972306.
78. Iung B, Armoiry X, Vahanian A et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail 2019;21:16191627.
79. Stone GW, Lindenfeld J, Abraham WT et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:23072318.
80. Mehra MR, Vaduganathan M, Fu M et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J 2019;40:3593-3602
145
81. Seferović PM, Coats AJS, Ponikowski P et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020 Feb;22(2):196-213.
82. Roumie CL, Min JY, D’Agostino McGowan et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc 2017;6. 83. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients
with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136.
84. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.
85. Packer M, Anker SD, Butler J et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021 Jan 26;143(4):326-336.
86. Sato Y, Yoshihisa A, Kimishima Y et al. Low T3 Syndrome Is Associated With High Mortality in Hospitalized Patients With Heart Failure. J Card Fail. 2019 Mar;25(3):195-203.
87. Stott DJ, Rodondi N, Kearney PM et al. Thyroid hormone therapy for older adults with